http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Tyme Technologies (TYME) Reports FY22 Net Loss of $23M, Cash Position of $84M
-
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results
-
Tyme Technologies (TYME) Announces Board Changes
-
TYME Technologies, Inc. Announces Changes to its Board of Directors
-
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
Tyme Technologies (TYME) Reports Q3 EPS of ($0.03), Provides Business Update
-
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
-
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
-
Tyme Technologies (TYME) Announces Discontinuation of SM-88 and MPS Tria
-
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
-
TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference
-
Tyme Technologies (TYME) Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
-
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
-
TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
-
Tyme Technologies (TYME) Issues Business Update; Reports Q2 Earnings
-
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
-
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
-
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
-
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
-
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
-
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
-
TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET
-
Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
-
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
-
Tyme Technologies (TYME) Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports FY21 Financial Results
-
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
-
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
-
Tyme Technologies (TYME) Announces Frank L. Porfido as CFO
-
TYME Appoints Frank L. Porfido as Chief Financial Officer
-
TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting
-
TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer
-
Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
-
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
-
TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium
-
Tyme Inc. (TYME) Highlights New Preclinical Data Showing Anti-Cancer Effect of Cancer Metabolism-Based Pipeline Candidate, TYME-18
-
TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020
-
Tyme Inc. (TYME) Highlights New Preclinical Data Supporting SM-88 Mechanism of Action
-
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020
-
LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial
-
Tyme Technologies Inc. (Nasdaq: TYME) to Ring The Nasdaq Stock Market Opening Bell

